Evotec nabs Gates Foundation cash for low-income country COVID-19 antibody work

Seattle-based Just – Evotec Biologics received funding from The Bill & Melinda Gates Foundation to seek out and work on new monoclonal antibody (mAb) drugs to help combat severe forms of COVID-19.

The company, which is the U.S. subsidiary of German biotech-CRO hybrid Evotec, will put the money towards developing antibody treatment candidates that work against severe COVID-19 in vulnerable populations in low and middle income countries, which will likely be left behind in the development race as wealthier countries snap up new treatments and vaccines.

READ THE STORY at FierceBiotech »